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1What is the issue?
The 2010 Drug Strategy covers “dependence 
on all drugs, including prescription and over-the-
counter medicines,” and local responses to drug 
misuse and dependence are also expected to cover 
dependence and other problems with medicines 
(sometimes called addiction to medicines (ATM)).
The 2013 JSNA support pack for commissioners 
(NTA, 2012) suggested that commissioners ask:
• “Are innovative responses in place or being 
developed to prevent, identify and treat 
evidenced and emerging need in relation to 
addiction to prescribed and over-the-counter 
medicines?”
And that prescription and over-the-counter (OTC)
medicines are included in wider considerations of:
• Waiting times for community-based interventions 
that provide access within three weeks of referral
• The treatment system’s ability to respond rapidly 
and effectively to changing patterns of substance 
misuse. 
What medicines and who is using them?
Although dependence on prescribed 
benzodiazepines in the community receives 
most media attention, health and public health 
commissioners will want to ensure that locally 
appropriate responses are available for problems 
with a full range of prescription and OTC medicines, 
including, but not limited to:
• Benzodiazepines and z-drugs, prescribed mainly 
for anxiety (benzodiazepines only) and insomnia
• Opioid and some other pain medicines, both 
prescribed and bought over-the-counter
• Stimulants, prescribed for ADHD or slimming
• Some OTC cough and cold medicines, and anti-
histamines and stimulants.
There is a fuller list at appendix A.
There are distinct but overlapping populations 
using these medicines and they may need different 
approaches:
• Those who use prescription and OTC medicines 
as a supplement or alternative to illicit drugs, or 
as a commodity to sell
• Those who overuse prescription or OTC 
medicines to cope with genuine or perceived 
physical or psychological symptoms
• Those for whom the prescribed use of a 
medicine inadvertently led to dependence, 
sometimes called involuntary or iatrogenic 
addiction.
Problems with prescription medicines occur in 
the community and in secure environments but 
the medicines used, populations using them and 
reasons for misuse or dependence may differ.
Health and wellbeing boards, through their joint 
strategic needs assessment (JSNA) and joint health 
and wellbeing strategy, will want to support health 
and public health commissioners to understand 
local need in relation to addiction to medicines, so 
that together they can commission appropriate 
responses. Health commissioners will likely 
include both NHS England local teams and clinical 
commissioning groups.
Understanding local need
Commissioners will want a full picture of who is 
misusing or dependent on what medicines from 
which sources in order to commission appropriate 
local responses.
Sources of data
Date on prescriptions dispensed in the community 
is made available to local partnerships via the 
prescribing toolkit provided by NHS Prescription 
Services. There is more information in the NTA’s 
Addiction to medicine report (NTA, 2011) and from 
the NHS Business Services Authority.
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commissioning groups (CCGs) for information on the 
prescribing patterns of GPs.
The NTA’s JSNA support pack for strategic partners  
– sent to every partnership – includes local NDTMS 
data on people in treatment for prescription and OTC 
medicines, and drug users who have a problem with 
these as well as illicit drugs (see below).
National Drug Treatment Monitoring System 
(NDTMS) quarterly (or Green) reports include data 
on presenting substance that can be used to 
track changes in the profile of medicines causing 
problems.
However, NDTMS data only covers those seeking 
specialist treatment so may not be most useful for 
gaining an understanding of people who do not 
approach treatment services or as a source of early 
intelligence on developing problems with medicines.
Other useful local data sources may include any 
local ATM and primary-care services that do not 
report to NDTMS.
Other ways of finding out
Controlled drugs accountable officers (CDAOs) 
monitor, audit and ensure the safe management 
and use of drugs controlled under the Misuse 
of Drugs Act. CDAOs in NHS England local 
area teams are the accountable officers for their 
CD local intelligence networks and they have a 
surveillance role over community prescribing and 
pharmacies. NHS trusts and independent hospitals 
are also required to appoint CDAOs. Many of the 
medicines listed in appendix A are controlled drugs 
so will be considered by accountable officers in 
their work.
Commissioners might also request practice or 
service-based audits of case notes to inform future 
commissioning.
Consultation with those affected by addiction to 
medicines or likely to encounter it in their work 
is an invaluable source of additional information. 
Appropriate local consultees might include service 
users (drug & alcohol treatment, mental health), 
treatment and other service providers, peer mentors 
and volunteers, pharmacy groups, police, probation, 
primary and social care staff, tenancy and housing 
support services, etc.
It has been agreed nationally that the New Medicine 
Service (NMS) and Medicines Use Reviews (MUR) 
are not suited to improving benzodiazepine 
prescribing.
What’s different about prisons and other 
secure environments?
The medicines used, and reasons for their use, in 
secure environments generally mirror those in the 
general population although the scale and nature 
may differ. Prisoners may be more likely than the 
general population to suffer from conditions such 
as insomnia, anxiety and pain that lead them to 
seek medicines liable to dependence. They may 
also be more likely to claim these conditions as a 
way of obtaining medicines for personal misuse or 
as currency. They will also have less access to OTC 
medicines.
PHE will publish a guide on managing persistent 
pain in secure environments, in June 2013. This will 
complement Safer Prescribing in Prisons (RCGP, 
2011). 
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People in treatment for prescription-only medicines (POM) or over the counter medicines (OTC), and drug users who have a problem with these as well 
as illicit drugs are presented below. The drug strategy encourages local areas to ensure their services have the capacity to help people get the support 
that they need for POM and OTC dependence.
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Figure 1: Example of JSNA data
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Prevention
This guide is concerned with the treatment of 
problems of dependence that have arisen in people 
prescribed certain medicines or buying them. 
However, commissioners will also want to consider 
how problems can be prevented. Primary and 
secondary healthcare, public health and social care 
can together contribute to:
• Ensuring that psychological and other treatments 
are available as alternatives to prescribing 
medicines, including through the Increasing 
Access to Psychological Therapies (IAPT) 
programme
• Ensuring that the public and patients are aware 
of the problems that can arise with these 
medicines, and understand why their availability 
may be limited in duration or quantity
• Ensuring that doctors, pharmacists, social care 
staff and others are aware of current guidance on 
these medicines and are alert to any developing 
problems in patients
• Monitoring and responding to prescribing and 
purchasing patterns.
Who and where?
Primary care will be the first port of call for most 
patients dependent on prescription or OTC 
medicines.
If patients are not comfortable returning to the GP 
who prescribed the medicine on which they have 
become dependent, they have the right to see 
another GP or register with another practice.
Patients, and sometimes their GPs, may be unaware 
that there is a problem with a prescription or OTC 
medicine. ATM outreach services in primary care 
practices can help to identify problems and link 
patients to appropriate treatment.
Specialist responses can support and advise GPs 
to provide treatment and to recognise when a 
patient needs more specialist care, and can treat 
patients who cannot be treated in standard primary 
care. Commissioners will need to ensure that those 
providing specialist responses consider:
• The knowledge and expertise needed to treat 
patients, some of whom may have been using 
medicines for many years and may need long-
term withdrawal and extensive support, including 
for co-occurring and emerging mental and 
physical health problems
• Where and when interventions should be 
provided. Patients may be uncomfortable sharing 
space with those using illicit drugs and – whether 
ultimately this should be accepted or challenged 
– responses need to focus on engaging and 
retaining people, which may mean them 
providing (and commissioners funding) separate 
ATM sessions, premises or services.
These specialist responses may be in existing or 
newly-commissioned services that deal with a 
range of drug and alcohol issues or they may be 
complemented or better provided by separate, 
dedicated, ATM services and support groups. This 
is necessarily a local decision in response to local 
need, history and context.
This guide is not intended to provide clinical advice 
on withdrawal from long-term benzodiazepine 
dependence. However, commissioned treatment 
will be based on clinical advice, which you can 
read more about in the publications listed in ‘further 
reading’ below.
Commissioners will want to ensure that 
commissioned services include appropriate 
clinical governance mechanisms to ensure safe 
and effective prescribing of medicines liable to 
dependence and for the treatment of dependence, 
and to prevent and detect diversion of prescription 
medicines by patients.
How?
Primary care practices can be expected to respond 
to ATM problems as part of their regular patient care, 
within the terms of the General Medical Services 
(GMS) contract.
Specialist responses will usually be commissioned 
as part of the drug and alcohol misuse treatment 
system, from one or more of the following, as locally 
appropriate:
• Primary care (providing an enhanced service)
• A provider of integrated drug and alcohol 
treatment services
• A dedicated (often voluntary sector) ATM provider.
It will also be important to ensure that pain 
management, mental health, and drug and alcohol 
treatment services work together and provide 
coordinated and integrated responses to patients.
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informal support groups to fully-fledged service 
provider organisations – may have arisen and been 
supported in a number of ways, including:
• From member support and donations
• Fundraising and charitable trust funding
• Directly commissioned locally:
 As part of drug treatment by the NHS or   
 local authority
 As part of mental health treatment by the   
 NHS or local authority
• Funded as part of local authority support for the 
voluntary and community sector.
Commissioners contracting with voluntary sector 
providers will want to consider and honour The 
Compact between government and the voluntary 
and community sector so that, for instance, services 
are given multi-year funding where possible.
A checklist for consideration of addiction to 
medicines in needs assessment is included as 
Appendix B.
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Further reading
The Faculty of Pain Medicine has published guidance 
on the commissioning of local pain services.
Commissioners wanting to better understand 
the clinical issues involved in treating addiction to 
medicines can refer to the following:
• The British National Formulary contains current 
advice on appropriate prescribing and on 
withdrawal
• The NICE Clinical Knowledge Summary on 
benzodiazepine and z-drug withdrawal provides 
an accessible summary of the evidence base 
and guidance on best practice for primary care 
practitioners 
• Drug Misuse and Dependence: UK Guidelines 
on Clinical Management is principally concerned 
with the treatment of those dependent on illicit 
drugs but also covers benzodiazepine misuse 
and dependence
• The Ashton manual describes a widely-
supported protocol for withdrawal from long-term 
benzodiazepine dependence
• The British Pain Society publishes a range of 
professional guidance on clinical and other pain 
matters
A range of NICE guidance covers the use of 
medicines for insomnia, anxiety, pain, etc that are 
liable to misuse and dependence. 
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dependence 
Notes:
• The proper or generic medicine name is followed 
by:
 notes or other names, including those used  
 in medicine combinations, in brackets ()
 example brand names, some no longer   
 available in UK, in square brackets []
• The list does not distinguish between medicines 
that are prescription-only or available over-
the-counter without a prescription (either from 
pharmacies only or from any shop, often only in 
limited quantities). For more information, see the 
British National Formulary
• The remit of this guide is restricted to medicines 
with psychoactive properties, as is this list. Other 
medicines, such as, for example, laxatives and 
anabolic steroids, may also be liable to misuse 
but are not included here.
• A comprehensive list of medicines recorded in 
the National Drug Treatment Monitoring System 
is contained in annex 1 of the NTA’s 2011 
Addiction to medicine report.
Benzodiazepines and z-drugs
• Benzodiazepines
 Chlordiazepoxide [Librium]
 Diazepam [Valium]
 Loprazolam
 Lorazepam [Ativan]
 Nitrazepam [Mogadon]
 Oxazepam
 Temazepam
 Clonazepam
• Z-drugs (although z-drugs differ chemically 
from the benzodiazepines, they have the same 
pharmacological properties)
 Zaleplon [Sonata] 
 Zolpidem [Stilnoct] 
 Zopiclone [Zimovane]
Opioid pain medicines
• Pethidine
• Methadone [Physeptone]
• Oxycodone [OxyNorm]
• Tramadol [Zydol]
• Codeine (with paracetamol = co-codamol) 
[Nurofen Plus]
• Dihydrocodeine (with paracetamol = co-
dydramol) [Paramol]
Epilepsy and pain medicines
• Pregabalin (also licensed for anxiety) [Lyrica]
• Gabapentin
Stimulants
• Methylphenidate [Ritalin]
• Dexamfetamine
• Modafinil
• Caffeine [Pro-plus]
Some cough and cold, anti-diarrhoea, 
and anti-allergy medicines
• Opium tincture [Gee’s linctus]
• Codeine linctus
• Anhydrous morphine [J.Collis Browne’s Mixture]
• Kaolin and morphine
• Sedative antihistamines such as promethazine 
[Phenergan] and diphenhydramine [Benadryl, 
Nytol]
Some people also report problems withdrawing 
from antidepressants (e.g. amitriptyline, fluoxetine 
[Prozac], paroxetine [Seroxat], venlafaxine [Efexor]), 
and it is generally best to taper off the dose of 
an antidepressant rather than stop it suddenly. 
However, there is no clear evidence that these 
medicines can produce dependence according to 
internationally accepted criteria.
Commissioning treatment for dependence on 
prescription and over-the-counter medicines:  
a guide for NHS and local authority commissioners
6Appendix B. Commissioning for addiction to 
medicines: needs assessment checklist 
Range of medicines:
• Benzodiazepines and z-drugs – prescribed and 
illicitly obtained
• Opioid and some other pain medicines – 
prescription, OTC and illicitly obtained
• Stimulants, prescribed for ADHD or slimming
• Other OTC medicines
Range of users:
• Prescription and OTC medicines as a 
supplement or alternative to illicit drugs, or as a 
commodity to sell
• Overuse of prescription or OTC medicines to 
cope with genuine or perceived physical or 
psychological symptoms
• Inadvertently dependent following prescribed use 
of a medicine
Range of environments:
• Community
• Hospitals
• Secure environments
Existing services/responses:
• Primary care
• Specialist treatment
• Voluntary sector support groups and services
Data sources:
• NHS Prescription Services
• JSNA support data from NDTMS
• Quarterly (Green) NDTMS reports
• Local ATM and primary care services
Consult:
• Clinicians (doctors, pharmacists, nurses, etc and 
their local groups)
• Current, potential and past service users
• Controlled drugs accountable officers
Joint work between HWBs and local and 
national commissioners, specifying their 
current and desired provision, etc.
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